Preprint / Version 1

A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives

Authors

  • Abas Sezer Genetics and Bioengineering, International University of Sarajevo, Sarajevo, Bosnia and Herzegovina
  • Mervisa Halilović-Alihodžić Genetics and Bioengineering, International University of Sarajevo, Sarajevo, Bosnia and Herzegovina
  • Annissa Vanwieren Genetics and Bioengineering, International University of Sarajevo, Sarajevo, Bosnia and Herzegovina
  • Adna Smajkan Fakultät Chemie und Pharmazie, Ludwig-Maximilians-Universität München, Munich, Germany
  • Amina Karić Genetics and Bioengineering, International University of Sarajevo, Sarajevo, Bosnia and Herzegovina
  • Husein Djedović Genetics and Bioengineering, International University of Sarajevo, Sarajevo, Bosnia and Herzegovina
  • Jasmin Šutković Genetics and Bioengineering, International University of Sarajevo, Sarajevo, Bosnia and Herzegovina

Keywords:

COVID-19, Drug repurposing, Herbal medicine, Remdesivir, Ivermectin

Abstract

COVID-19 is an illness caused by severe acute respiratory syndrome coronavirus 2. Due to its rapid spread, in March 2020 the World Health Organization (WHO) declared pandemic. Since the outbreak of pandemic many governments, scientists, and institutions started to work on new vaccines and finding of new and repurposing drugs. Main body of the abstract Drug repurposing is an excellent option for discovery of already used drugs, effective against COVID-19, lowering the cost of production, and shortening the period of delivery, especially when preclinical safety studies have already been performed. There are many approved drugs that showed significant results against COVID-19, like ivermectin and hydrochloroquine, including alternative treatment options against COVID-19, utilizing herbal medicine. Short conclusion This article summarized 11 repurposing drugs, their positive and negative health implications, along with traditional herbal alternatives, that harvest strong potential in efficient treatments options against COVID-19, with small or no significant side effects. Out of 11 repurposing drugs, four drugs are in status of emergency approval, most of them being in phase IV clinical trials. The first repurposing drug approved for clinical usage is remdesivir, whereas chloroquine and hydrochloroquine approval for emergency use was revoked by FDA for COVID-19 treatment in June 2020. Keywords: COVID-19, Drug repurposing, Herbal medicine, Remdesivir, Ivermectin

Downloads